By VETTAPHARMA reporter: Sanofi has announced that its investigational drug rilzabrutinib has received a Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and an orphan drug designation from the Japanese Ministry of Health, Labour and Welfare for the treatment of warm autoimmune hemolytic anemia (wAIHA), a rare autoimmune disorder characterized by the premature destruction of red blood cells.
Rilzabrutinib, marketed as Wayrilz® in approved indications, is a novel oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor that helps address complex immune-system dysregulation through multi-immune modulation. It is the first and only investigational BTK inhibitor for wAIHA to receive Breakthrough Therapy designation from the FDA. The Japanese orphan designation recognizes rilzabrutinib’s potential to treat a rare disease with significant unmet clinical need.
These regulatory designations are based on clinical data from the ongoing LUMINA 2 Phase 2b study (clinical study identifier: NCT05002777), which evaluates the efficacy and safety of rilzabrutinib in patients with wAIHA. The LUMINA 3 Phase 3 study (NCT07086976) is also underway, comparing rilzabrutinib with placebo in the same patient population. There are currently no approved therapies that specifically target the underlying cause of wAIHA, which can lead to anemia, fatigue, and serious organ damage.
The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of medicines for serious or life-threatening conditions when preliminary clinical evidence indicates the therapy may show substantial improvement over existing options. Similarly, orphan drug designation in Japan is granted to medicines intended to address rare diseases with high unmet needs.
Rilzabrutinib is already approved under the brand name Wayrilz for the treatment of immune thrombocytopenia (ITP) in the United States, European Union, and United Arab Emirates, and is under regulatory review for ITP in Japan. Beyond wAIHA, rilzabrutinib is being studied in other rare diseases, including IgG4-related disease and sickle cell disease, though these uses remain investigational.
Source credit:
- Sanofi. (2026, February 9). Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia. Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
